Abstract:Abstract Introduction: Immunotherapy is promising for patients with treatment-refractory head and neck squamous cell carcinoma (HNSCC). However, greater than 80% do not respond to checkpoint inhibitors, suggesting that the highly immunosuppressive immune microenvironment of HNSCC mediates therapeutic resistance. Our group has developed a novel treatment platform utilizing clinically translatable RNA-nanoparticles (NPs) to remodel the systemic and intratumoral HNSCC immune microenvironment to enable potent immunotherapeutic activity. Objective: The purpose of this study is to examine the immunologic effects and antitumor efficacy of tumor-derived RNA-NPs in murine models of oral cavity squamous cell carcinoma (OCSCC). Materials and Methods: Tumor-derived RNA-NPs were prepared by complexing in vitro transcribed mRNA from MOC1 cells (syngeneic murine oral cavity squamous cell carcinoma cell line) with nanoliposomes. These complexes were injected into MOC1 tumor-bearing C57BL/6 mice. Immunogenicity was determined from spleens and tumors by multiparameter flow cytometry and qPCR analysis. Efficacy was assessed based on subcutaneous tumor volume measurements. Results: Personalized tumor RNA-NPs mediated significant increases in systemic and tumor-infiltrating lymphocytes (TILs). Compared to control animals, RNA-NPs increased peripheral CD8+ T cells (p=0.0007) and decreased regulatory immune cells [CD4+CD25+FoxP3+ (Tregs)] (p=0.0043). WIthin the tumor microenvironment, RNA-NPs increased intratumoral CD3+CD8+ T cells (p =0.0278) and CD3+CD4+ T cells (p=0.0307). qPCR on MOC1 tumors revealed elevated expression of the effector cytokine interferon-γ (NP alone vs. RNA-NP; fold change 1.309 vs. 90.13) and reduced gene expression of arginase-1 (NP alone vs. RNA-NP; fold change 1.29 vs. 0.005), suggesting that RNA-NPs can attenuate the immunosuppressive microenvironment. Compared to control animals or mice receiving PD-L1 monotherapy, RNA-NPs mediated significantly greater antitumor efficacy based on subcutaneous tumor volume measurements (p<0.0001, mixed effects analysis). Conclusion: RNA-NPs reprogram the peripheral and intratumoral HNSCC immune microenvironments and unlock antitumor activity in preclinical models. We have successfully generated tumor-derived RNA-NPs as a renewable resource that can be made readily available for HNSCC patients from a small tissue sample. FDA-IND enabling studies are currently under way in preparation for first-in-human trials. Citation Format: Natalie L. Silver, Rekha R. Garg, Hector R. Mendez-Gomez, Kristianna Fredenberg, Spencer Barnes, Frances L. Weidert, Peter Dziegielewski, Sayour J. Elias, Duane A. Mitchell. Personalized RNA nanoparticles remodel the HNSCC immunologic milieu to unlock immunotherapeutic activity [abstract]. In: Proceedings of the AACR-AHNS Head and Neck Cancer Conference: Optimizing Survival and Quality of Life through Basic, Clinical, and Translational Research; 2019 Apr 29-30; Austin, TX. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(12_Suppl_2):Abstract nr A18.

A bioconvergence study on platinum-free concurrent chemoradiotherapy for the treatment of HPV-negative head and neck carcinoma

Non‐Persistent Nano‐Architectures Enhance Concurrent Chemoradiotherapy in an Immunocompetent Orthotopic Model of HPV+ Head/Neck Carcinoma

Neoadjuvant Hyperthermia Combined with Hybrid Nanoarchitectures Enhances Chemoradiotherapy Efficacy in Head and Neck Carcinoma

[Concurrent simultaneous integrated boost radiotherapy and cetuximab in head and neck squamous cell cancer patients: is it feasible in daily clinical practice?]

Abstract 224: Combining functional precision medicine and radiotherapy with bio-printed organoids in head and neck squamous cell carcinoma

Evolution of a Paradigm Switch in Diagnosis and Treatment of HPV-Driven Head and Neck Cancer-Striking the Balance Between Toxicity and Cure

Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy

Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma

New use of metals as nanosized radioenhancers

Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists

Co-Adjuvant Nanoparticles for Radiotherapy Treatments of Oncological Diseases

Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

Insights into Gold Nanoparticles Possibilities for Diagnosis and Treatment of the Head and Neck Upper Aerodigestive Tract Cancers

Abstract A18: Personalized RNA nanoparticles remodel the HNSCC immunologic milieu to unlock immunotherapeutic activity

Radioimmunotherapy in HPV-Associated Head and Neck Squamous Cell Carcinoma

Enhanced radiosensitivity and chemoradiation efficacy in nasopharyngeal carcinoma via a dual-targeted SPION@polymer hybrid nanosensitizer

Nanomedicine in HNSCC therapy-a challenge to conventional therapy

Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.

Neoadjuvant Capecitabine in Operable HPV-Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting

New Frontiers in Colorectal Cancer Treatment Combining Nanotechnology with Photo- and Radiotherapy

Proof of Concept for Dual Anticancer Effects by a Novel Nanomaterial-Mediated Cancer Cell Killing and Nano-Radiosensitization